Washington: US’s Pfizer and its German partner BioNTech will soon submit its pivotal trial’s data to the US Food and Drug Administration (FDA) concerning eligibility and safety of the mRNA Covid-19 vaccine for kids aged 5 to 11. Albert Bourla, Pfizer chief, on ABC’s This Week stated they will soon be turning in their submission for review and authorisation. These results come after the very first trial globally in kids below 12 as the Moderna trial for this age group is still ongoing.
During the trial, the kids were given a two-dose regimen of 10 mg 21 days apart, as compared to 30mg which is for older age groups. The public will still have to wait a while before the manufacturing for these vaccines begins post final analysis, given the FDA authorizes it.
In a joint statement by the two pharma giants, it was made clear that the vaccine was to be administered at a lower dosage than for people who were above the age of 12. Pfizer chief Bourla also mentioned how it’s extremely crucial to consider vaccinating younger kids as the spread of the Delta variant poses a considerable threat to kids too.
Safeguarding kids will also help in overall education as countries have now started to open schools after a wide gap. This significant update arrives at a sensitive time as countries globally fight the Delta variant currently. The pandemic has been prolonged for so long, and with vaccine hesitancy in several adults across all countries, it becomes even more necessary to spread awareness around its safety and efficiency.
